Sunshine Biopharma Inc. - Understand $sbfm stock

$SBFM Market Cap: $5.939 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$32.96M

TTM

Gross Margin

30.99%

TTM

Net Earnings

-$4.226M

TTM

Current Assets

$25.98M

Q3 2024

Current Liabilities

$4.528M

Q3 2024

Current Ratio

573.74%

Q3 2024

Total Assets

$30.06M

Q3 2024

Total Liabilities

$5.018M

Q3 2024

Book Value

$25.04M

Q3 2024

Cash

$12.21M

Q3 2024

P/E

-1.405

Nov 29, 2024 EST

Free Cash Flow

-$14.00M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$24.09M	$4.346M	$228.4K	$71.41K	$21.12K	$0.00	$0.00	$0.00	$1.710K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	454.42%	1802.38%	219.89%	238.12%				-100.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$24.09M	$4.346M	$228.4K	$71.41K	$21.12K	$0.00	$0.00	$0.00	$1.710K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$15.75M	$2.649M	$117.8K	$25.85K	$11.05K	$0.00
Gross Profit	$8.339M	$1.697M	$110.6K	$45.56K	$10.07K	$0.00
Gross Profit Margin	34.61%	39.04%	48.42%	63.8%	47.68%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Selling, General & Admin	$11.12M	$29.28M	$1.866M	$547.4K	$515.5K	$1.024M	$774.7K	$841.6K	$638.8K	$1.160M	$1.710M	$590.0K	$380.0K	$470.0K	$50.00K	$20.00K	$10.00K	$10.00K
YoY Change	-62.02%	1469.07%	240.83%	6.19%	-49.66%	32.2%	-7.96%	31.76%	-44.94%	-32.16%	189.83%	55.26%	-19.15%	840.0%	150.0%	100.0%	0.0%
% of Gross Profit	133.34%	1725.56%	1686.96%	1201.54%	5119.46%
Research & Development	$1.856M	$811.9K	$672.2K	$60.95K	$15.20K	$12.80K	$0.00	$32.79K	$8.660K	$330.0K	$140.0K	$0.00	$140.0K	$0.00
YoY Change	128.59%	20.77%	1002.89%	300.99%	18.75%		-100.0%	278.64%	-97.38%	135.71%		-100.0%
% of Gross Profit	22.25%	47.85%	607.78%	133.78%	150.94%
Depreciation & Amortization	$149.2K	$25.16K	$12.74K	$14.07K	$13.77K	$49.36K	$6.630K	$60.73K	$4.250K	$0.00
YoY Change	492.81%	97.49%	-9.45%	2.18%	-72.1%	644.49%	-89.08%	1328.94%
% of Gross Profit	1.79%	1.48%	11.52%	30.88%	136.74%
Operating Expenses	$13.12M	$30.09M	$2.551M	$622.4K	$544.5K	$1.051M	$781.3K	$935.2K	$651.7K	$1.490M	$1.850M	$610.0K	$530.0K	$470.0K	$50.00K	$20.00K	$10.00K	$10.00K
YoY Change	-56.38%	1079.56%	309.8%	14.31%	-48.2%	34.55%	-16.45%	43.5%	-56.26%	-19.46%	203.28%	15.09%	12.77%	840.0%	150.0%	100.0%	0.0%
Operating Profit	-$4.785M	-$27.00M	-$2.440M	-$576.9K	-$534.4K	-$1.051M
YoY Change	-82.28%	1006.53%	322.99%	7.94%	-49.16%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Interest Expense	$674.4K	$39.41K	-$320.9K	-$160.4K	-$131.0K	-$101.9K	-$106.1K	-$34.73K	-$307.0K	-$180.0K	-$10.00K	$0.00	$0.00		-$10.00K	-$10.00K	$0.00	$0.00
YoY Change	1611.2%	-112.28%	100.06%	22.43%	28.52%	-3.95%	205.56%	-88.69%	70.56%	1700.0%					0.0%
% of Operating Profit
Other Income/Expense, Net	$674.4K	$489.6K	$0.00	$3.000K	$1.370K	$0.00	$0.00	$380.00	$9.520K	$0.00	-$550.0K	$20.00K	$10.00K	$0.00	$0.00
YoY Change	37.75%		-100.0%	118.98%			-100.0%	-96.01%		-100.0%	-2850.0%	100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Pretax Income	-$4.111M	-$26.51M	-$12.44M	-$2.784M	-$1.078M	-$2.138M	-$1.040M	-$3.497M	-$1.653M	-$1.930M	-$2.490M	-$710.0K	-$560.0K	-$540.0K	-$1.200M	-$30.00K	-$10.00K	-$10.00K
YoY Change	-84.49%	113.17%	346.7%	158.25%	-49.58%	105.52%	-70.25%	111.55%	-14.36%	-22.49%	250.7%	26.79%	3.7%	-55.0%	3900.0%	200.0%	0.0%
Income Tax	$395.2K	$233.3K	$0.00	$0.00	$0.00	$0.00				$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.506M	-$26.74M	-$12.44M	-$2.784M	-$1.660M	-$2.156M	-$1.040M	-$3.497M	-$1.653M	-$1.930M	-$2.490M	-$710.0K	-$560.0K	-$540.0K	-$1.200M	-$30.00K	-$10.00K	-$10.00K
YoY Change	-83.15%	115.05%	346.7%	67.69%	-23.0%	107.28%	-70.25%	111.55%	-14.36%	-22.49%	250.7%	26.79%	3.7%	-55.0%	3900.0%	200.0%	0.0%
Net Earnings / Revenue	-18.7%	-615.44%	-5444.32%	-3898.74%	-7861.22%				-96661.4%
Basic Earnings Per Share	-$0.19	-$1.76	-$4.76
Diluted Earnings Per Share	-$18.52	-$1.76	-$4.761M	-$2.728M	-$30.37M	-$141.6M	-$95.35M	-$658.5M	-$5.407M	-$583.1K	-$898.9K	-$285.1K	-$363.6K	-$362.4K	-$1.008M	-$63.83K	-$21.28K	-$21.28K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Cash & Short-Term Investments	$16.29M	$21.83M	$2.045M	$989.9K	$40.50K	$110.5K	$107.5K	$57.45K	$50.80K	$140.0K	$30.00K	$130.0K	$60.00K	$160.0K	$110.0K	$0.00	$10.00K	$10.00K
YoY Change	-25.35%	967.22%	106.61%	2344.17%	-63.36%	2.79%	87.17%	13.09%	-63.71%	366.67%	-76.92%	116.67%	-62.5%	45.45%		-100.0%	0.0%
Cash & Equivalents	$16.29M	$21.83M	$2.045M	$989.9K	$40.50K	$110.5K	$107.5K	$57.45K	$50.80K	$140.0K	$30.00K	$130.0K	$60.00K	$160.0K	$110.0K	$0.00	$10.00K	$10.00K
Short-Term Investments
Other Short-Term Assets	$310.6K	$283.8K	$37.22K	$10.37K	$8.850K	$990.9K	$9.670K	$1.010K	$3.110K		$0.00	$0.00	$50.00K	$50.00K	$0.00	$0.00	$0.00	$0.00
YoY Change	9.44%	662.49%	258.92%	17.18%	-99.11%	10147.26%	857.43%	-67.52%				-100.0%	0.0%
Inventory	$5.735M	$3.290M	$105.7K	$23.77K	$15.91K	$0.00
Prepaid Expenses
Receivables	$2.552M	$1.912M	$7.800K	$1.920K	$430.00	$0.00
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.89M	$27.31M	$2.196M	$1.026M	$65.69K	$1.101M	$117.2K	$58.46K	$53.91K	$140.0K	$30.00K	$130.0K	$110.0K	$210.0K	$110.0K	$0.00	$10.00K	$10.00K
YoY Change	-8.87%	1143.83%	114.03%	1461.79%	-94.04%	839.8%	100.48%	8.44%	-61.49%	366.67%	-76.92%	18.18%	-47.62%	90.91%		-100.0%	0.0%
Property, Plant & Equipment	$1.013M	$1.155M	$7.060K	$19.53K	$32.46K	$45.12K	$60.00K	$5.940K	$4.310K
YoY Change	-12.3%	16254.96%	-63.85%	-39.83%	-28.06%	-24.8%	910.1%	37.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets							$80.29K
YoY Change
Total Long-Term Assets	$2.457M	$1.932M	$7.060K	$19.53K	$32.45K	$45.12K	$140.3K	$5.940K	$619.4K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	27.2%	27258.64%	-63.85%	-39.82%	-28.08%	-67.84%	2261.78%	-99.04%
Total Assets	$27.35M	$29.24M	$2.203M	$1.045M	$98.14K	$1.147M	$257.5K	$64.40K	$673.3K	$140.0K	$30.00K	$130.0K	$110.0K	$210.0K	$110.0K	$0.00	$10.00K	$10.00K
YoY Change
Accounts Payable	$2.585M	$2.803M	$42.94K	$62.87K	$96.88K	$115.8K	$19.31K	$0.00	$80.49K	$30.00K	$20.00K	$0.00	$0.00	$10.00K	$10.00K	$10.00K	$0.00	$0.00
YoY Change	-7.75%	6427.25%	-31.7%	-35.11%	-16.36%	499.84%		-100.0%	168.3%	50.0%			-100.0%	0.0%	0.0%
Accrued Expenses	$118.7K	$123.0K	$48.29K	$24.32K	$21.08K	$9.290K	$9.220K	$9.010K	$2.660K	$20.00K	$0.00	$0.00	$0.00			$0.00	$0.00	$0.00
YoY Change	-3.54%	154.77%	98.56%	15.37%	126.91%	0.76%	2.33%	238.72%	-86.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00	$964.1K	$715.6K	$662.8K	$722.6K	$237.0K	$1.141M	$480.0K	$10.00K	$60.00K	$0.00			$20.00K	$0.00	$0.00
YoY Change			-100.0%	34.73%	7.97%	-8.28%	204.94%	-79.22%	137.62%	4700.0%	-83.33%
Total Short-Term Liabilities	$5.552M	$6.931M	$91.23K	$1.051M	$833.5K	$912.5K	$751.1K	$274.1K	$1.270M	$530.0K	$40.00K	$60.00K	$0.00	$10.00K	$10.00K	$20.00K	$0.00	$0.00
YoY Change	-19.9%	7497.29%	-91.32%	26.13%	-8.65%	21.48%	174.04%	-78.42%	139.68%	1225.0%	-33.33%		-100.0%	0.0%	-50.0%
Long-Term Debt	$0.00	$0.00	$1.900M	$949.0K	$0.00	$0.00	$79.71K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%	100.21%			-100.0%
Other Long-Term Liabilities	$539.0K	$642.2K				$289.9K		$0.00	$0.00
YoY Change	-16.07%
Total Long-Term Liabilities	$539.0K	$642.2K	$1.900M	$949.0K	$0.00	$289.9K	$79.71K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-16.07%	-66.2%	100.21%		-100.0%	263.63%
Total Liabilities	$6.140M	$7.616M	$1.991M	$2.000M	$833.5K	$1.202M	$830.9K	$274.1K	$1.270M	$530.0K	$40.00K	$60.00K	$0.00	$10.00K	$10.00K	$20.00K	$0.00	$0.00
YoY Change	-19.39%	282.49%	-0.45%	139.98%	-30.67%	44.71%	203.12%	-78.42%	139.68%	1225.0%	-33.33%		-100.0%	0.0%	-50.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	24.33M shares	15.18M shares	2.612M shares
Diluted Shares Outstanding	24.33M shares	15.18M shares	2.612M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $5.939 Million

About Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fort Lauderdale, Florida and currently employs 44 full-time employees. The company went IPO on 2008-08-15. Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The firm offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The firm has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The company also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.

Industry: Pharmaceutical Preparations Peers: Liminal BioSciences Inc. Xenon Pharmaceuticals Inc.